Brief: Maxcyte Says H1 Revenues Expected To Be Up About 21%
17/07/2019 07:37
July 17 (Reuters) - MaxCyte Inc MXCT.L :
* MAXCYTE, INC. MAXCYTE, INC. - MXCR - TRADING UPDATE
* MAXCYTE INC SAYS H1 2019 REVENUES ARE EXPECTED TO INCREASE
APPROXIMATELY 21% YEAR-ON-YEAR TO $8.4M (2018: $6.9M)
* MAXCYTE INC SAYS CO IS TRADING IN LINE WITH EXPECTATIONS
FOR
FULL YEAR
Source text for Eikon: ID:nRSQ7557Fa
Further company coverage: MXCT.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MaxCyte
See all newsMaxCyte, Inc. MaxCyte, Inc. - MXCR - Second Price Monitoring Extn
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Price Monitoring Extension
Brief: Maxcyte And Allogene Therapeutics Sign Clinical And Commercial License Agreement To Enable The Advancement Of Allogeneic Car T (Allocar T™) Therapies
Brief: Maxcyte Signs Agreement With KSQ Therapeutics
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Agreement with KSQ Therapeutics